Washington D.C., DC Clinical Trials Report — July 2026

Washington, D.C., participants should act promptly if they match a study nearing its enrollment deadline: 42 recruiting trials are expected to close within the next 90 days. Four of those studies accept healthy volunteers. The most common closing-soon areas include prostate cancer, cancer, pain, stroke, and neurogenic bladder, with 2 trials in each category.

The District currently has 824 recruiting trials across 281 research facilities. Only 4 new studies opened in July, down from 16 in June and 8 in May. That slower pace makes the active closing-soon studies particularly relevant for people who are ready to be screened now.

Conditions with enrollment windows closing soon

People considering a trial should contact the listed research site rather than wait for the projected closing date. Studies may stop accepting participants earlier if they reach their enrollment goals.

• Prostate cancer (2 trials)
• Cancer (2 trials)
• Pain (2 trials)
• Stroke (2 trials)
• Neurogenic bladder (2 trials)
• Bleeding, bipolar I disorder, appendicitis, chronic kidney diseases, and cervical cancer (1 trial each)

Healthy volunteers have 4 closing-soon opportunities, while 87 healthy-volunteer trials are recruiting across Washington, D.C., overall. However, none of July’s four new openings accepts healthy volunteers, so people without a related medical condition should search the existing pool rather than focus only on newly opened studies.

July’s standout new Phase 3 opportunity

July’s new studies cover cardiovascular disease, dietary fiber and inulin, insulin resistance, the gastrointestinal microbiome, skeletal muscle, and several forms of neuroendocrine carcinoma. The four openings include 2 drug trials, 1 device study, and 1 dietary-supplement study.

• AbbVie is sponsoring NCT07728188, a Phase 3 study enrolling 520 adults with relapsed or refractory multiple myeloma. The trial evaluates injected etentamig plus oral pomalidomide against standard therapies and measures adverse events and changes in disease activity.
• Boehringer Ingelheim is one of the industry sponsors represented among July’s new openings, adding another major pharmaceutical option for eligible local patients.
• Imbed Biosciences is sponsoring a new study classified among the month’s device-related research.
• George Washington University sponsors one of the new studies, reflecting the District’s continuing academic research activity alongside industry trials.

Three of the four new trials are industry-sponsored and one is categorized as other sponsorship. The new-study mix does not include a trial specifically open to children. One is female-only, and 3 include older adults. These details can help potential participants quickly narrow searches, although each protocol has additional requirements involving diagnosis, disease stage, medications, age, and prior treatment.

Where D.C. has the greatest research access

Children’s National Medical Center has the largest reported local portfolio, with 94 recruiting trials. MedStar Georgetown University Hospital and Children’s National Hospital each list 70, followed closely by MedStar Washington Hospital Center with 69. These institutions provide access to a broad range of pediatric, adult, hospital-based, and university-affiliated research.

• Children's National Medical Center (94 trials)
• MedStar Georgetown University Hospital (70 trials)
• Children's National Hospital (70 trials)
• MedStar Washington Hospital Center (69 trials)
• Sibley Memorial Hospital (46 trials)
• Georgetown University (35 trials)
• Georgetown University Medical Center (34 trials)
• Research Site (26 trials)
• Medstar Washington Hospital Center (23 trials)
• George Washington University Medical Center (20 trials)
• George Washington University (19 trials)
• Medstar Georgetown University Hospital (14 trials)

The facility names show some overlap between hospital, university, and protocol-specific listings, so participants should verify the exact location and contact details for an individual study. People seeking cancer, cardiovascular, neurological, pain, or hospital-based research may find the broadest set of options through MedStar, Georgetown, George Washington University, and Sibley. Families looking for pediatric research should begin with Children’s National listings.

Eligibility and next steps for volunteers

July’s four new trials include no studies specifically identified as accepting healthy volunteers. One is female-only, none include children, and three include older adults. Across all recruiting studies, however, the District has 87 opportunities for healthy volunteers. Eligibility may involve age, sex, medication restrictions, laboratory tests, previous diagnoses, or time spent at the research site.

Patients with prostate cancer, other cancers, pain, stroke, neurogenic bladder, bleeding disorders, bipolar I disorder, appendicitis, chronic kidney disease, or cervical cancer should review the closing-soon listings first. Healthy volunteers should compare the broader recruiting database and ask whether screening is still open, particularly for the four studies approaching their projected end dates.

Searching beyond Washington, D.C.

The supplied data does not identify nearby cities with recruiting trials, so no additional District of Columbia locations can be recommended from this month’s dataset. Participants who can travel should ask each study team whether affiliated sites exist outside the city or search by condition and study phase in neighboring areas.

With July openings falling to 4 after 16 in June, the next monthly update will show whether the local pipeline rebounds. In the meantime, D.C.’s large existing research base gives eligible patients and volunteers a reason to contact high-volume facilities early and monitor new listings as summer enrollment decisions unfold.